Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 3.53%82.23M | 8.96%42.11M | 228.06%13.08M | -41.48%8.55M | -16.68%18.49M | 81.42%79.43M | 167.82%38.65M | -9.47%3.99M | 120.76%14.6M | 21.05%22.19M |
Net income from continuing operations | 15.04%72.32M | 4.95%17.87M | 14.57%18.34M | 20.33%18.62M | 21.82%17.5M | 18.77%62.87M | 28.00%17.03M | 16.47%16M | 29.68%15.47M | 2.92%14.37M |
Operating gains losses | -90.26%19K | -94.64%6K | 833.33%22K | -108.33%-8K | 90.00%-1K | 650.00%195K | 11,300.00%112K | 66.67%-3K | 231.03%96K | -242.86%-10K |
Depreciation and amortization | -6.37%20.07M | -17.75%4.65M | 0.61%5.08M | -11.96%4.7M | 4.51%5.65M | -3.60%21.44M | 0.98%5.65M | -10.69%5.05M | 4.40%5.33M | -8.10%5.41M |
Other non cash items | -31.25%44K | -29.41%12K | -33.33%10K | -27.78%13K | -35.71%9K | -24.71%64K | -29.17%17K | -21.05%15K | -25.00%18K | -22.22%14K |
Change In working capital | -50.47%-13.18M | 24.19%18.85M | 39.23%-11.01M | -111.29%-15.58M | -452.56%-5.45M | 75.21%-8.76M | 396.33%15.18M | -12.24%-18.11M | 36.46%-7.38M | 162.53%1.55M |
-Change in receivables | -415.66%-12.5M | -35.69%8.14M | 28.35%-7.92M | -54.90%1.98M | -621.09%-14.7M | 118.12%3.96M | 2,770.46%12.66M | -3.96%-11.05M | 229.08%4.39M | 72.28%-2.04M |
-Change in payables and accrued expense | 159.39%2.13M | 104.62%137K | -717.34%-2.46M | -85.02%899K | 150.57%3.55M | -177.26%-3.58M | -2.45%-2.96M | -19.11%398K | -15.12%6M | -20,529.41%-7.01M |
-Change in other current assets | 198.91%5.34M | 582.70%6.25M | -17.11%-4.35M | 82.27%-292K | 197.30%3.74M | -170.11%-5.4M | -158.07%-1.3M | -380.74%-3.72M | -151.60%-1.65M | 31.07%1.26M |
-Change in other current liabilities | 71.29%-2.56M | 116.51%2.6M | 29.98%3.2M | 34.09%-9.08M | -39.77%721K | -11.08%-8.91M | -83.11%1.2M | 155.20%2.46M | -44.54%-13.77M | 205.37%1.2M |
-Change in other working capital | -208.16%-5.59M | -69.01%1.73M | 108.38%520K | -287.19%-9.1M | -84.64%1.25M | 129.07%5.17M | 150.36%5.58M | -116.61%-6.21M | 73.72%-2.35M | 59.78%8.14M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 3.53%82.23M | 8.96%42.11M | 228.06%13.08M | -41.48%8.55M | -16.68%18.49M | 81.42%79.43M | 167.82%38.65M | -9.47%3.99M | 120.76%14.6M | 21.05%22.19M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 118.42%13.41M | -47.34%-14.95M | 73.04%21.27M | 145.76%12.56M | 88.47%-5.47M | -485.05%-72.78M | -504.53%-10.14M | -1.59%12.29M | -356.16%-27.45M | -175.49%-47.47M |
Capital expenditure reported | -9.44%-7.13M | -14.00%-1.76M | -11.97%-1.83M | -8.58%-1.82M | -3.56%-1.72M | -6.91%-6.52M | -24.64%-1.54M | -9.79%-1.64M | -3.58%-1.68M | 5.04%-1.66M |
Net PPE purchase and sale | -5.94%-2.68M | 0.48%-419K | -61.64%-1.13M | 14.06%-666K | 26.50%-466K | 6.55%-2.53M | -5.25%-421K | 33.52%-696K | 3.49%-775K | -39.96%-634K |
Net intangibles purchase and sale | --0 | --0 | --0 | --0 | --0 | 11.50%-177K | --0 | --0 | --0 | ---177K |
Net business purchase and sale | 95.35%-375K | --0 | --0 | ---- | ---- | -132.54%-8.06M | -806,100.00%-8.06M | --0 | ---- | ---- |
Net investment purchase and sale | 142.51%23.59M | -10,540.00%-12.77M | 65.66%24.22M | 161.71%15.43M | 92.69%-3.29M | -213,557.69%-55.5M | -175.47%-120K | -2.69%14.62M | -19,583.46%-25M | -199.37%-45M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 118.42%13.41M | -47.34%-14.95M | 73.04%21.27M | 145.76%12.56M | 88.47%-5.47M | -485.05%-72.78M | -504.53%-10.14M | -1.59%12.29M | -356.16%-27.45M | -175.49%-47.47M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -29.86%-56.28M | -2,389.72%-2.66M | -47.55%-14.15M | -20.11%-16.57M | -15.38%-22.89M | 25.76%-43.34M | -107K | 24.34%-9.59M | 46.73%-13.8M | -0.24%-19.84M |
Net issuance payments of debt | 0.00%-19.8M | --0 | --0 | --0 | 0.00%-19.8M | 0.00%-19.8M | --0 | --0 | --0 | 0.00%-19.8M |
Cash dividends paid | -13.07%-31.82M | ---2.03M | 1.35%-14.15M | ---- | ---- | 27.05%-28.14M | --0 | -13.16%-14.35M | ---- | ---- |
Proceeds from stock option exercised by employees | -97.96%98K | --0 | --0 | ---- | ---- | --4.81M | --54K | --4.76M | ---- | ---- |
Net other financing activities | -2,188.94%-4.76M | -291.30%-630K | --0 | ---1.03M | -6,491.49%-3.1M | ---208K | ---161K | --0 | --0 | ---47K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -29.86%-56.28M | -2,389.72%-2.66M | -47.55%-14.15M | -20.11%-16.57M | -15.38%-22.89M | 25.76%-43.34M | ---107K | 24.34%-9.59M | 46.73%-13.8M | -0.24%-19.84M |
Net cash flow | ||||||||||
Beginning cash position | -20.94%126.72M | 50.58%146.15M | 37.16%122.65M | 0.03%116.69M | -20.94%126.72M | -15.75%160.29M | -33.93%97.06M | -36.64%89.42M | -31.90%116.65M | -15.75%160.29M |
Current changes in cash | 207.24%39.35M | -13.72%24.5M | 202.12%20.19M | 117.03%4.54M | 78.11%-9.88M | -35.73%-36.69M | 122.67%28.4M | 58.61%6.68M | -5.30%-26.65M | -141.35%-45.13M |
Effect of exchange rate changes | -176.06%-2.38M | -652.46%-6.96M | 245.00%3.31M | 339.70%1.42M | -109.82%-147K | 206.91%3.13M | 104.21%1.26M | -38.97%960K | 87.86%-592K | 734.32%1.5M |
End cash Position | 29.18%163.69M | 29.18%163.69M | 50.58%146.15M | 37.16%122.65M | 0.03%116.69M | -20.94%126.72M | -20.94%126.72M | -33.93%97.06M | -36.64%89.42M | -31.90%116.65M |
Free cash flow | 2.93%72.21M | 8.46%39.78M | 513.69%10.09M | -50.19%6.05M | -17.25%16.3M | 102.03%70.16M | 191.78%36.67M | -10.85%1.64M | 190.24%12.14M | 22.13%19.7M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |